The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.皇冠体育官网app（www.hg108.vip）是一个开放皇冠体育官网代理APP下载、皇冠体育官网会员APP下载、皇冠体育官网线路APP下载、皇冠体育官网登录APP下载的皇冠体育官网平台。皇冠体育官网APP上最新登录线路、新2皇冠体育官网更新最快。皇冠体育官网APP开放皇冠体育官网会员注册、皇冠体育官网代理开户等业务。
PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.
The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.
The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.
The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.,
Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.
Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.
UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg